Brief: Egetis Therapeutics's Emcitate Gets Orphan Drug Designation From FDA

Egetis Therapeutics AB (publ)

18/02/2022 10:58

Feb 18 (Reuters) - Egetis Therapeutics AB (publ)  EGTX.ST :
    * FDA GRANTS ORPHAN DRUG DESIGNATION TO EMCITATE® FOR
TREATMENT OF
RESISTANCE TO THYROID HORMONE TYPE BETA (RTH-Β)
    * U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED AN
ORPHAN
DRUG DESIGNATION (ODD) TO COMPANY'S LEADING CANDIDATE DRUG
EMCITATE® (TIRATRICOL) FOR TREATMENT OF RESISTANCE TO THYROID
HORMONE TYPE BETA (RTH-B)

Source text for Eikon:  ID:nMFNbtSRXW 
Further company coverage:  EGTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))